BPH Global Registry

Condition(s) studied

Study summary

Benign prostatic hyperplasia (BPH) is one of the most common performed surgical procedures in urology. Over the past few decades there have been an increasing development of newer surgical treatment options. Additionally, the outcome parameters for BPH treatments have been standardized. While data are available for the initial pivotal studies, post-market release data are lacking. Under the umbrella of uCARE, we have started a prospective, ongoing international registry for recording demographics and outcomes for patients undergoing surgical treatments for BPH.

Eligibility

Primary outcome measure(s)

• International Prostate Symptom Score (IPSS) — 36 months
  Comparison of mean IPSS score change between baseline and at each follow-up during the course of the study. The scale goes from 0 (Mild) to 35 (Severe).
• Quality of Life (QoL) — 36 months
  Comparison of mean QoL score change between baseline and at each follow-up during the course of the study. The scale is a single question which ranges from 0 to 6, with higher numbers indicating a worse quality of life.
• Post-Void Residual (PVR) — 36 months
  Comparison of mean PVR change between baseline and at each follow-up during the course of the study.
• Complications (including incontinence) — 36 months
  Type and Clavien grade incidences across all surgical interventions.

Trial sites (30)